Cargando…

Clinical outcomes of patients with COVID-19 and inflammatory rheumatic diseases receiving biological/targeted therapy

BACKGROUND: Anti-cytokine treatments are used in the treatment of severe COVID-19. Other studies have shown statistical significance with TNF inhibitors but not with other biological/targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARD). OBJECTIVES: Compare the rate of severe acute r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pehlivan, Özlem, Aydin, Tutku
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	King Faisal Specialist Hospital and Research Centre 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167456/ https://www.ncbi.nlm.nih.gov/pubmed/35658585 http://dx.doi.org/10.5144/0256-4947.2022.155

Ejemplares similares

Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies
por: Sanchez-Piedra, Carlos, et al.
Publicado: (2020)

COVID-19 Among Patients With Inflammatory Rheumatic Diseases
por: Esatoglu, Sinem Nihal, et al.
Publicado: (2021)

Evaluation of the relationship between acute kidney injury and renin angiotensin system inhibition in COVID-19 patients
por: Yesil, Ezgi Ersoy, et al.
Publicado: (2022)

Attitudes of patients with a rheumatic disease on drug use in the COVID-19 pandemic
por: Coskun, Belkıs Nihan, et al.
Publicado: (2021)

COVID-19, chronic inflammatory rheumatic disease and anti-rheumatic treatments
por: Ouédraogo, Dieu-Donné, et al.
Publicado: (2020)

The effects of COVID-19 infection on the mortality of patients receiving rituximab therapy
por: Ekin, Ali, et al.
Publicado: (2022)

Residual Pain in the Context of Selecting and Switching Biologic Therapy in Inflammatory Rheumatic Diseases
por: Berghea, Florian, et al.
Publicado: (2021)

Editorial: Autoimmune and Inflammatory Rheumatic Diseases: Identifying Biomarkers of Response to Therapy With Biologics
por: Giuliani, Anna Lisa, et al.
Publicado: (2021)

Outcomes of COVID-19 in Inflammatory Rheumatic Diseases: A Retrospective Cohort Study
por: Alhowaish, Thamer Saad, et al.
Publicado: (2022)

Clinical characteristics and outcome of COVID-19 in patients with rheumatic diseases
por: Alzahrani, Zeyad A., et al.
Publicado: (2021)

Outcome measures in inflammatory rheumatic diseases
por: Fransen, Jaap, et al.
Publicado: (2009)

COVID-19 vaccination in individuals with inflammatory rheumatic diseases
por: Skapenko, Alla, et al.
Publicado: (2022)

Risk of Malignancy and Biologic Therapy in Rheumatic Inflammatory Diseases: A Single-center Experience
por: Cometi, Laura, et al.
Publicado: (2020)

Role of Biologic Therapies in the Rheumatic Manifestations of Inflammatory Bowel Disease: A Systematic Analysis
por: Nag, Aiswarya, et al.
Publicado: (2023)

Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study
por: Álvaro Gracia, Jose María, et al.
Publicado: (2021)

The First Effect of COVID-19 Pandemic on Starting Biological Disease Modifying Anti-Rheumatic Drugs: Outcomes from the TReasure Real-Life Database
por: Alpay Kanıtez, Nilüfer, et al.
Publicado: (2022)

Rheumatic disease and COVID-19: epidemiology and outcomes
por: Hyrich, Kimme L., et al.
Publicado: (2020)

Management of acute abdomen during the active disease course of COVID-19 and multisystem inflammatory syndrome in children
por: Boybeyi-Turer, Ozlem, et al.
Publicado: (2022)

COVID-19 presentation and outcomes in patients with inflammatory rheumatic and musculoskeletal diseases receiving IL6-receptor antagonists prior to SARS-CoV-2 infection
por: Comarmond, Cloé, et al.
Publicado: (2023)

Implications of COVID-19 for the management of patients with inflammatory rheumatic diseases
por: Richez, Christophe, et al.
Publicado: (2020)

Autoimmune inflammatory rheumatic diseases post-COVID‐19 vaccination
por: Safary, Azam, et al.
Publicado: (2022)

Does COVID-19 cause an increased risk of hospitalization or death in patients with inflammatory rheumatic diseases treated with biological DMARDs or targeted synthetic DMARDs?
por: Lwin, May, et al.
Publicado: (2020)

Editorial: Autoimmune and inflammatory rheumatic diseases: Identifying biomarkers of response to therapy with biologics: Volume II
por: Giuliani, Anna Lisa, et al.
Publicado: (2023)

Comparisons of Clinical Features and Outcomes of COVID-19 between Patients with Pediatric Onset Inflammatory Rheumatic Diseases and Healthy Children
por: Haslak, Fatih, et al.
Publicado: (2022)

Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs
por: Michelena, Xabier, et al.
Publicado: (2020)

Theory, Targets and Therapy in Rheumatic Diseases
por: Bosnić, Dubravka
Publicado: (2006)

EP09 COVID-19 and rheumatic disease clinical characteristics and outcomes of rheumatic disease patients hospitalised with COVID-19: a single centre experience
por: Cheila, Myrto, et al.
Publicado: (2020)

Pregnancy Outcomes Associated With Biologic Agent Exposure in Patients With Several Rheumatic Diseases and Inflammatory Bowel Diseases
por: Ahn, Soo Min, et al.
Publicado: (2023)

Vaccines in adults with autoimmune inflammatory rheumatic disease: What are the knowledge and attitudes of physicians?
por: Badak, Suade Özlem
Publicado: (2022)

Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?
por: Santos, Cristiana Sieiro, et al.
Publicado: (2021)

The Importance of Outcome Measures in the Management of Inflammatory Rheumatic Diseases
por: Molina Collada, Juan, et al.
Publicado: (2021)

PReS13-SPK-1586: Biological agents for the treatment of rheumatic diseases: present and future targets of biologic therapy
por: Mcinnes, I
Publicado: (2013)

COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study
por: Avouac, Jérôme, et al.
Publicado: (2021)

Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study
por: Shin, Youn Ho, et al.
Publicado: (2021)

Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy
por: Ceribelli, Angela, et al.
Publicado: (2020)

Anti-Drug Antibodies in the Biological Therapy of Autoimmune Rheumatic Diseases
por: Pizano-Martinez, Oscar, et al.
Publicado: (2023)

Immunogenicity against the BNT162b2 mRNA COVID-19 Vaccine in Rheumatic Disease Patients Receiving Immunosuppressive Therapy
por: Sugihara, Koichi, et al.
Publicado: (2022)

Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes
por: Kastritis, Efstathios, et al.
Publicado: (2020)

The Recent Outbreak of COVID-19 in China During the Omicron Variant Predominance: Clinical Features and Outcomes in Patients with Autoimmune Inflammatory Rheumatic Diseases
por: Geng, Yan, et al.
Publicado: (2023)

COVID-19 prevalence and outcomes in patients receiving biologic therapies at an infusion center in New York City
por: Harada, Kaoru, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_578rop5ors3nsptjfocbra7n9l